Microalgae‐Based Hydrogel for Inflammatory Bowel Disease and Its Associated Anxiety and Depression

Abstract

AbstractPatients diagnosed with inflammatory bowel disease (IBD) exhibit a notable prevalence of psychiatric disorders, such as anxiety and depression. Nevertheless, the etiology of psychiatric disorders associated with IBD remains uncertain, and an efficacious treatment approach has yet to be established. Herein, we propose an oral hydrogel strategy (SP@Rh‐gel) for co‐delivery of Spirulina platensis and rhein to treat IBD and IBD‐associated anxiety and depression by modulating the microbiota‐gut‐brain axis. SP@Rh‐gel improves the solubility, release characteristics and intestinal retention capacity of the drug, leading to a significant improvement in the oral therapeutic efficacy. Oral administration of SP@Rh‐gel inhibits NF‐κB‐caspase‐1 signaling pathway to reduce intestinal inflammation and rebalances the disrupted intestinal microbial community to maintain intestinal homeostasis. Furthermore, SP@Rh‐gel maintains intestinal barrier integrity and reduces the release of pro‐inflammatory cytokines and lipopolysaccharides and their entry into the hippocampus through the blood‐brain barrier, thereby inhibiting neuroinflammation and maintaining neuroplasticity. SP@Rh‐gel significantly alleviates the colitis symptoms, as well as anxiety‐ and depression‐like behaviors, in a chronic colitis mouse model. This study demonstrates the significant involvement of the microbiota‐gut‐brain axis in the development of IBD with psychiatric disorders and proposes a safe, simple, and highly efficient therapeutic approach for managing IBD and comorbid psychiatric disorders.This article is protected by copyright. All rights reserved